[go: up one dir, main page]

MX2019009781A - Sistema terapeutico transdermico transparente que contiene nicotina. - Google Patents

Sistema terapeutico transdermico transparente que contiene nicotina.

Info

Publication number
MX2019009781A
MX2019009781A MX2019009781A MX2019009781A MX2019009781A MX 2019009781 A MX2019009781 A MX 2019009781A MX 2019009781 A MX2019009781 A MX 2019009781A MX 2019009781 A MX2019009781 A MX 2019009781A MX 2019009781 A MX2019009781 A MX 2019009781A
Authority
MX
Mexico
Prior art keywords
tts
nicotine
transdermal therapeutic
therapeutic system
containing transparent
Prior art date
Application number
MX2019009781A
Other languages
English (en)
Inventor
Wauer Gabriel
Seibertz Frank
Hille Thomas
Botzem Petra
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2019009781A publication Critical patent/MX2019009781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J7/00—Adhesives in the form of films or foils
    • C09J7/30—Adhesives in the form of films or foils characterised by the adhesive composition
    • C09J7/38—Pressure-sensitive adhesives [PSA]
    • C09J7/381—Pressure-sensitive adhesives [PSA] based on macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C09J7/385—Acrylic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a sistemas terapéuticos transparentes (TTS) que contienen la nicotina como sustancia activa y que también contienen por lo menos un grupo amida ácida como grupo funcional lateral; el TTS puede ser transparente y para uso discreto; la invención también se refiere a métodos para producir estos TTS, dichos TTS son producidos por métodos que usan dichos polímeros y son cargados con la sustancia activa por medio de un método de impresión.
MX2019009781A 2017-02-27 2018-02-26 Sistema terapeutico transdermico transparente que contiene nicotina. MX2019009781A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017104026.9A DE102017104026A1 (de) 2017-02-27 2017-02-27 Nicotin enthaltendes transparentes transdermales therapeutisches System
PCT/DE2018/100168 WO2018153413A1 (de) 2017-02-27 2018-02-26 Nicotin enthaltendes transparentes transdermales therapeutisches system

Publications (1)

Publication Number Publication Date
MX2019009781A true MX2019009781A (es) 2019-10-14

Family

ID=61837471

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009781A MX2019009781A (es) 2017-02-27 2018-02-26 Sistema terapeutico transdermico transparente que contiene nicotina.

Country Status (12)

Country Link
US (1) US11964060B2 (es)
EP (1) EP3585440B1 (es)
JP (1) JP7149951B2 (es)
KR (1) KR20190120263A (es)
CN (1) CN110325216A (es)
AU (1) AU2018226365A1 (es)
CA (1) CA3051150C (es)
DE (1) DE102017104026A1 (es)
ES (1) ES2897449T3 (es)
MX (1) MX2019009781A (es)
RU (1) RU2019127802A (es)
WO (1) WO2018153413A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019117310A1 (de) * 2019-06-27 2020-12-31 Lts Lohmann Therapie-Systeme Ag Verfahren zur Herstellung von Wirkstoffverabreichungssystemen mittels Tampondruckverfahren
KR102477606B1 (ko) 2022-07-02 2022-12-14 주식회사 아이써치마케팅 Sns 빅데이터 분석 시스템
KR102477604B1 (ko) 2022-07-02 2022-12-14 주식회사 아이써치마케팅 온라인 마케팅 빅데이터 분석 시스템

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196817A (ja) 1983-04-21 1984-11-08 Sekisui Chem Co Ltd 貼付剤
DE3727232A1 (de) 1987-08-14 1989-02-23 Lohmann Therapie Syst Lts Verfahren zur herstellung einer darreichungs- und/oder dosierungsform fuer arzneimittelwirkstoffe
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4908213A (en) 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
US5508038A (en) 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
DE4400769C2 (de) 1994-01-13 1996-07-18 Lohmann Therapie Syst Lts Verfahren und Vorrichtung zur Herstellung einer flächigen Darreichungsform mit einer Arzneimittelwirkstoffe enthaltenden Zubereitung
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
NZ504108A (en) 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
CZ302035B6 (cs) * 1998-12-18 2010-09-15 Alza Corporation Prostredek pro transdermální podání nikotinu
DE19912477A1 (de) 1999-03-19 2000-09-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System und Verfahren zu seiner Herstellung
EP1233763B1 (de) 1999-11-29 2003-07-30 LTS Lohmann Therapie-Systeme AG Transdermale therapeutische systeme mit verbesserter stabilität und ein verfahren zu ihrer herstellung
US6479076B2 (en) 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
DE10304988A1 (de) * 2003-02-07 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
RU2263503C1 (ru) 2004-04-23 2005-11-10 Каш Тенгиз Способ получения препарата и препарат для трансдермального введения никотина
DE102004062614B4 (de) * 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
DE102005010255A1 (de) * 2005-03-07 2006-09-14 Lts Lohmann Therapie-Systeme Ag Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung
JP5000910B2 (ja) 2006-03-29 2012-08-15 リンテック株式会社 貼付剤及びその製造方法
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
RU2320674C1 (ru) 2006-07-12 2008-03-27 Каш Тенгис Способ получения сополимера n-винилпирролидона с лаурилметакрилатом для трансдермального введения никотина, сополимер, полученный этим способом, гель для трансдермального введения никотина
RU2356553C2 (ru) 2007-04-06 2009-05-27 Каш Тенгис Способ получения препарата и препарат для трансдермального введения никотина
US9511021B2 (en) 2008-05-21 2016-12-06 Novartis, A.G. Tablettable chewing gums
GB201100790D0 (en) 2011-01-18 2011-03-02 Kraft Foods Global Brands Llc Hydrophilic gum base
JP5725940B2 (ja) 2011-04-01 2015-05-27 日東電工株式会社 ニコチン含有貼付製剤
WO2014198423A1 (de) * 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
DE102014000200A1 (de) 2014-01-03 2015-07-09 Michael Horstmann Transdermales Therapeutisches System

Also Published As

Publication number Publication date
DE102017104026A1 (de) 2018-08-30
BR112019017151A2 (pt) 2020-04-14
CN110325216A (zh) 2019-10-11
ES2897449T3 (es) 2022-03-01
RU2019127802A (ru) 2021-03-29
KR20190120263A (ko) 2019-10-23
JP2020518553A (ja) 2020-06-25
US20200230074A1 (en) 2020-07-23
WO2018153413A1 (de) 2018-08-30
EP3585440B1 (de) 2021-09-01
AU2018226365A1 (en) 2019-08-22
CA3051150A1 (en) 2018-08-30
EP3585440A1 (de) 2020-01-01
RU2019127802A3 (es) 2021-03-29
JP7149951B2 (ja) 2022-10-07
US11964060B2 (en) 2024-04-23
CA3051150C (en) 2023-10-03

Similar Documents

Publication Publication Date Title
EP4600271A3 (en) Bioactive molecule conjugate, preparation method and use thereof
MX382195B (es) Sistema terapeutico transdermico que contiene asenapina
SG10201907367QA (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
EP4599847A3 (en) Prefusion coronavirus spike proteins and their use
EA201691448A1 (ru) Гибридосомы, содержащие их композиции, способы их получения и их применения
PH12017500158A1 (en) Silicone-containing acrylic polymers for transdermal drug delivery compositions
MY177912A (en) Vegf neutralizing prodrugs for the treatment of ocular conditions
AU2017242867A8 (en) Vortioxetine pamoic acid salt and crystal form thereof
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
MY181540A (en) Transdermal composition containing donepezil as active ingredient
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
WO2012158437A3 (en) Cannula apparatus and ventricular assist systems using the cannula apparatus
EA201992832A1 (ru) Подкожное введение adamts13
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
MX2019009781A (es) Sistema terapeutico transdermico transparente que contiene nicotina.
MY197524A (en) System of multiple bags and method for the preparation of hemocomponents
EA201691741A1 (ru) Фармацевтическая композиция
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.
WO2015176801A8 (de) Lavendelöl enthaltendes transdermales therapeutisches system